Canceropole du Grand Ouest

Nantes, France

Canceropole du Grand Ouest

Nantes, France
Time filter
Source Type

PubMed | University of Tours, Hospital Virgen Of La Arrixaca, University of Murcia, Canceropole du Grand Ouest and CHRU de Tours
Type: | Journal: Nature communications | Year: 2016

The development of metastases largely relies on the capacity of cancer cells to invade extracellular matrices (ECM) using two invasion modes termed mesenchymal and amoeboid, with possible transitions between these modes. Here we show that the SCN4B gene, encoding for the 4 protein, initially characterized as an auxiliary subunit of voltage-gated sodium channels (Na

Chantome A.,French Institute of Health and Medical Research | Potier-Cartereau M.,French Institute of Health and Medical Research | Clarysse L.,French Institute of Health and Medical Research | Fromont G.,CHRU de Poitiers | And 16 more authors.
Cancer Research | Year: 2013

The SK3 channel, a potassium channel, was recently shown to control cancer cell migration, a critical step in metastasis outgrowth. Here, we report that expression of the SK3 channel was markedly associated with bone metastasis. The SK3 channel was shown to control constitutive Ca2+ entry and cancer cell migration through an interaction with the Ca2+ channel Orai1. We found that the SK3 channel triggers an association with the Orai1 channel within lipid rafts. This localization of an SK3-Orai1 complex seemed essential to control cancer cell migration. This suggests that the formation of this complex in lipid rafts is a gain-offunction, because we showed that none of the individual proteins were able to promote the complete phenotype. We identified the alkyl-lipid Ohmline as a disrupting agent for SK3-Orai1 lipid raft localization. Upon Ohmline treatment, the SK3-Orai1 complex moved away from lipid rafts, and SK3-dependent Ca2+ entry, migration, and bone metastases were subsequently impaired. The colocalization of SK3 and Orai1 in primary human tumors and bone metastases further emphasized the clinical relevance of our observations. Targeting SK3-Orai1 in lipid rafts may inaugurate innovative approaches to inhibit bone metastases. © 2013 American Association for Cancer Research.

Girault A.,French Institute of Health and Medical Research | Haelters J.-P.,French National Center for Scientific Research | Potier-Cartereau M.,French Institute of Health and Medical Research | Chantome A.,French Institute of Health and Medical Research | And 11 more authors.
Current Cancer Drug Targets | Year: 2011

Edelfosine is an inhibitor of SK3 channel-mediated cell migration. However, this compound bears adverse in vivo side effects. Using cell SK3 dependent cell-migration assay, patch-clamp, 125I-apamin binding, and in vivo experiments we tested the ability of 15 lipid derivatives with chemical structures inspired from edelfosine to inhibit SK3 channels. Using a structure-activity relationship approach we identified an edelfosine analog named Ohmline (1-O-hexadecyl-2-O-methyl-sn-glycero-3-lactose) with potent inhibitory effects on the SK3 channel. Its potency was greater for SK3 channels than for SK1 channels; it did not affect IKCa channels and only slightly but not significantly affected SK2 channels. This is the first SKCa channel blocker that can be used to discriminate between SK2 and SK1/SK3 channels and represents a useful tool to investigate the functional role of SK3 channels in peripheral tissues (that do not express SK1 channels). This compound, which acts with an IC 50 of 300 nM, did not displace apamin from SKCa channels and had no effect on non-specific edelfosine targets such as protein kinase C (PKC), receptors for platelet activating factor (PAF) and lysophosphatidic acid (LPA), as well as non-cancerous cells. This is promising because the pitfalls associated with the use of edelfosine-like compounds have been that their effective and high concentrations are often cytotoxic due to their detergent-like character causing normal cell lysis. Finally, Ohmline reduced metastasis development in a mice model of tumor indicating that this compound could become a lead compound for the first class of lipid-antimetastatic agent. © 2011 Bentham Science Publishers.

Driffort V.,University of Tours | Gillet L.,University of Tours | Bon E.,University of Tours | Marionneau-Lambot S.,Canceropole du Grand Ouest | And 11 more authors.
Molecular Cancer | Year: 2014

Background: NaV1.5 voltage-gated sodium channels are abnormally expressed in breast tumours and their expression level is associated with metastatic occurrence and patients' death. In breast cancer cells, NaV1.5 activity promotes the proteolytic degradation of the extracellular matrix and enhances cell invasiveness. Findings: In this study, we showed that the extinction of NaV1.5 expression in human breast cancer cells almost completely abrogated lung colonisation in immunodepressed mice (NMRI nude). Furthermore, we demonstrated that ranolazine (50 μM) inhibited NaV1.5 currents in breast cancer cells and reduced NaV1.5-related cancer cell invasiveness in vitro. In vivo, the injection of ranolazine (50 mg/kg/day) significantly reduced lung colonisation by NaV1.5-expressing human breast cancer cells. Conclusions: Taken together, our results demonstrate the importance of NaV1.5 in the metastatic colonisation of organs by breast cancer cells and indicate that small molecules interfering with NaV activity, such as ranolazine, may represent powerful pharmacological tools to inhibit metastatic development and improve cancer treatments. © 2014 Driffort et al.

Loading Canceropole du Grand Ouest collaborators
Loading Canceropole du Grand Ouest collaborators